Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.

AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...

Danish clinical-stage AI-based vaccine developer Evaxion Biotech (Nasdaq: EVAX) has entered into an option and license ...

US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated ...

Pfizer has withdrawn Oxbryta (voxelotor), a sickle cell disease treatment, from global markets due to new clinical data ...

Merck's Phase III KEYFORM-007 trial, testing a combination of favezelimab and Keytruda, failed to meet its primary endpoint ...

Evotec has entered a partnership with Novo Nordisk to develop next-generation off-the-shelf cell therapy technologies. Novo ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja (leniolisib) ...

Amgen's shares fell over 5% after updates on its Phase III immunology drug, rocatinlimab, raised investor concerns. While the ...

The US Food and Drug Administration (FDA) has approved a new indication for AstraZeneca’s Tagrisso (osimertinib), which is ...

Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara ...